- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00031993
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
PRIMARY OBJECTIVES:
I. To evaluate the antitumor cytostatic activity of OSI-774 as measured by the probability of surviving progression-free for at least 6 months in patients with persistent or recurrent squamous cell carcinoma of the cervix.
II. To determine the nature and degree of toxicity of OSI-774 in this cohort of patients.
SECONDARY OBJECTIVES:
I. To determine the partial and complete response rates in patients with squamous cell carcinoma of the cervix receiving OSI-774.
II. To determine the duration of progression-free survival and overall survival within this patient population treated with OSI-774.
III. Assess the effects of prognostic factors: initial performance status and age.
TERTIARY OBJECTIVES:
I. To determine epidermal growth factor receptor (EGFR) and p110 truncated EGFR (p110 sEGFR) isoform expression levels in primary tumors, and from tumor samples obtained pretreatment and following four weeks of therapy to determine tumor response (or resistance) to OSI-774 inhibition of the EGFR tyrosine kinase.
II. To correlate EGFR and p110sEGFR expression levels with either MAPK or AKT phosphorylation status in the same tissue samples obtained pretreatment and following four weeks of drug treatment to determine downstream effects with response to OSI-774 inhibition of EGFR.
III. To determine whether pretreatment serum p110 sEGFR concentrations are a useful prognostic indicator and whether altered and/or sEGFR concentrations are useful indicators of therapeutic responsiveness, time to progression, and overall survival in cervical carcinoma patients.
OUTLINE: This is a multicenter study.
Patients receive oral erlotinib once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19103
- Gynecologic Oncology Group
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Histologically confirmed squamous cell carcinoma (SCC) of the cervix
- Persistent or recurrent progressive disease
At least 1 prior systemic chemotherapy regimen for management of advanced, metastatic, or recurrent SCC of the cervix is required
- Chemotherapy administered as a radiosensitizer in conjunction with radiotherapy does not count as a systemic chemotherapy regimen
At least 1 unidimensionally measurable target lesion
- At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
- Lesions within a previously irradiated field are considered nontarget lesions unless disease progression or persistence is confirmed ≥ 90 days after completion of radiotherapy
- Tumor accessible for repeat needle biopsy
- Ineligible for a higher priority Gynecologic Oncology Group (GOG) protocol (any active GOG phase III protocol for the same patient population)
- Performance status - GOG 0-2 (for patients who have received only 1 prior regimen)
- Performance status - GOG 0-1 (for patients who have received 2 prior regimens)
- Platelet count at least 100,000/mm^3
- Absolute neutrophil count at least 1,500/mm^3
- Bilirubin no greater than upper limit of normal (ULN)
- SGOT no greater than 2.5 times ULN
- Alkaline phosphatase no greater than 2.5 times ULN
- Creatinine no greater than 1.5 times ULN
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- No abnormalities of the cornea (e.g., dry eye syndrome or Sjogren's syndrome)
- No congenital abnormalities (e.g., Fuch's dystrophy)
- No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)
- No abnormal corneal sensitivity test (Schirmer test or similar tear production test)
- No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
- No uncontrolled concurrent illness
- No ongoing or active infection requiring IV antibiotics
- No psychiatric illness or social situation that would preclude study compliance
- No grade 2 or greater sensory or motor neuropathy
- No prior allergic reactions attributed to compounds of similar chemical or biological composition to erlotinib
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- At least 3 weeks since prior immunologic therapy for SCC of the cervix
- One additional prior cytotoxic chemotherapy regimen for recurrent or persistent disease allowed
- At least 3 weeks since prior chemotherapy for SCC of the cervix and recovered
- No prior non-cytotoxic chemotherapy for recurrent or persistent disease
- At least 3 weeks since prior hormonal therapy for SCC of the cervix
- At least 3 weeks since prior radiotherapy for SCC of the cervix and recovered
- Recovered from recent prior surgery
- At least 3 weeks since other prior therapy for SCC of the cervix
- No prior epidermal growth factor receptor-targeting therapies
- No prior anticancer treatment that would preclude study participation
- No other concurrent investigational or commercial agents or therapies for SCC of the cervix
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Treatment (erlotinib hydrochloride)
Patients receive oral erlotinib once daily for 4 weeks.
Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
|
Korrelativa studier
Givet PO
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Progressionsfri överlevnad
Tidsram: Vid 6 månader
|
Vid 6 månader
|
Frequency and severity of adverse effects as measured by NCI CTC version 3.0
Tidsram: Up to 5 years
|
Up to 5 years
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Duration of overall survival
Tidsram: Up to 5 years
|
Up to 5 years
|
Duration of progression-free survival
Tidsram: Up to 5 years
|
Up to 5 years
|
Frequency of clinical response (complete and partial)
Tidsram: Up to 5 years
|
Up to 5 years
|
Prognostic factors including initial performance status and age
Tidsram: Up to 5 years
|
Up to 5 years
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neoplasmer, körtel och epitel
- Sjukdomsegenskaper
- Neoplasmer, skivepitelceller
- Carcinom
- Upprepning
- Karcinom, skivepitel
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Proteinkinashämmare
- Erlotinib hydroklorid
Andra studie-ID-nummer
- NCI-2012-02457
- U10CA027469 (U.S.S. NIH-anslag/kontrakt)
- GOG-0227D
- CDR0000069247 (Registeridentifierare: PDQ (Physician Data Query))
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Livmoderhalscancer skivepitel
-
Medtronic - MITGAvslutadEsophageal Squamous Cell Neoplasia (ESCN)Kina
-
Fudan UniversityAktiv, inte rekryterandeOligorecurrent och Oligometastatic Esophageal Squamous Cell CarcinomaKina
-
Newish Technology (Beijing) Co., Ltd.RekryteringHöggradig squamous intraepitelial lesion (HSIL)Kina
-
Fundació Institut de Recerca de l'Hospital de la...RekryteringCervikal intraepitelial neoplasi | Livmoderhalsdysplasi | Squamous intraepitelial lesioner i livmoderhalsenSpanien
-
Hoffmann-La RocheAvslutadIcke-Squamous icke-småcellig lungcancerTyskland
-
Antiva BiosciencesAvslutadLivmoderhalscancer | Mänskligt papillomvirus | HSIL, höggradiga skvamösa intraepitelial lesioner | Cervikal dysplasi | HSIL av livmoderhalsen | Höggradig cervikal intraepitelial neoplasi | HIV-negativ | CIN - Cervical Intraepitelial Neoplasia | Cervikal neoplasmSydafrika
-
Mabwell (Shanghai) Bioscience Co., Ltd.Har inte rekryterat ännuAvancerat clear cell renal cell carcinom
-
Brugmann University HospitalAvslutadHöggradig cervikal epitelial neoplasi (CIN2+)Belgien
-
University Hospital, Strasbourg, FranceOkändCervikal intraepitelial neoplasi grad 1 (CIN 1)Frankrike
-
Western Regional Medical CenterAvslutadAdenocarcinom i livmoderhalsen | Adenosquamous cell carcinom i livmoderhalsenFörenta staterna
Kliniska prövningar på laboratoriebiomarköranalys
-
Recep Tayyip Erdogan University Training and Research...Hacettepe UniversityAvslutadAmputation | Diabetisk polyneuropatiKalkon
-
Liao Jian AnRekryteringHuvud- och halscancerTaiwan
-
Oregon Health and Science University4DMedicalAnmälan via inbjudanLungsjukdomar | KOL | Luftvägssjukdom | DyspnéFörenta staterna
-
Progenity, Inc.AvslutadDowns syndrom | Aneuploidi | DiGeorges syndrom | Turnersyndrom | Klinefelters syndrom | Kromosomradering | Edwards syndrom | Pataus syndromFörenta staterna
-
University of California, San FranciscoRekryteringFriska | Fertilitetsstörningar | Manlig infertilitet | Infertilitet, manligFörenta staterna
-
Modarres HospitalAvslutadKomplikationer | Bildvägledd biopsi | Njure GlomerulusIran, Islamiska republiken
-
Medwave Estudios LimitadaAsociación Chilena de SeguridadOkändYrkesmässig exponering | Muskuloskeletala sjukdomarChile
-
Healthy.io Ltd.Avslutad
-
Duke UniversityIndragenAntikoagulations- och trombostest (AT-POCT)Förenta staterna
-
Bandim Health ProjectResearch Center for Vitamins and Vaccines, Statens Serum InstituteAvslutadSpädbarnsdödlighet | BCGGuinea-Bissau